Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer

被引：0
|
作者：
Jermann, P. [1 ]
Alborelli, I. [1 ]
Leonards, K. [1 ]
Rothschild, S. I. [2 ]
Leuenberger, L. [1 ]
Prince, S. Savic [1 ]
Mertz, K. [3 ]
Poechtrager, S. [3 ]
Zippelius, A. [2 ]
Quagliata, L. [4 ]
Bubendorf, L. [1 ]
机构：
[1] Univ Hosp Basel, Inst Pathol, Basel, Switzerland
[2] Univ Spital Basel, Basel, Switzerland
[3] Kantonsspital Liestal, Med Univ Klin, Liestal, Switzerland
[4] Univ Spital Basel, Pathol, Basel, Switzerland
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
161P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy
    Hendriks, Lizza E.
    Rouleau, Etienne
    Besse, Benjamin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 647 - 660
  • [42] Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer
    Lin, Gen
    Wang, Zhijie
    Chu, Qian
    Hu, Yi
    Huang, Dingzhi
    Wang, Jun
    Yang, Fan
    Zhong, Wenzhao
    Zhou, Chengzhi
    Zhu, Bo
    Ai, Xinghao
    Cao, Baoshan
    Cao, Yabing
    Chen, Mingqiu
    Chen, Xiaohui
    Chu, Tianqing
    Duan, Jianchun
    Fan, Yun
    Fang, Yong
    Feng, Shuitu
    Feng, Weineng
    Guo, Hui
    Han, Chengbo
    He, Yong
    Hong, Shaodong
    Hu, Jie
    Huang, Meijuan
    Huang, Yan
    Jiang, Da
    Jiang, Kan
    Jiang, Richeng
    Jin, Bo
    Jin, Shi
    Li, Jisheng
    Li, Min
    Li, Ziming
    Li, Chao
    Lin, Jie
    Liu, Anwen
    Liu, Si-Yang Maggie
    Yutao, Liu
    Liu, Zhefeng
    Liu, Zhe
    Liu, Zhenhua
    Liu, Zhentian
    Liu, Zhigang
    Lu, Yuping
    Lv, Tangfeng
    Ma, Zhiyong
    Miao, Qian
    THORACIC CANCER, 2024, 15 (05) : 419 - 426
  • [43] Chronological Effects of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Guo, Xinyue
    Qin, Lanqun
    Wang, Xinmeng
    Geng, Qian
    Li, Dongqing
    Lu, Yingying
    Jiang, Hua
    IMMUNOLOGY, 2025, 174 (04) : 402 - 410
  • [44] The role of immune checkpoint inhibitors in advanced non-small cell lung cancer
    Pistamaltzian, Nikolaos F.
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (05) : 435 - 447
  • [45] Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
    Miura, Yosuke
    Kasahara, Norimitsu
    Sunaga, Noriaki
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S628 - S632
  • [46] Safety of current immune checkpoint inhibitors in non-small cell lung cancer
    Abdayem, Pamela
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (06) : 651 - 667
  • [47] The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer
    Perdrizet, Kirstin
    Leighl, Natasha B.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (03)
  • [48] The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer
    Kirstin Perdrizet
    Natasha B. Leighl
    Current Treatment Options in Oncology, 2019, 20
  • [49] Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
    Wang, Shuai
    Hao, Jiatao
    Wang, Hao
    Fang, Yong
    Tan, Lijie
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [50] Immune checkpoint inhibitors in therapy of non-small cell lung cancer (a review)
    Kolesnik, O. P.
    Mykhailychenko, V. V.
    ZAPOROZHYE MEDICAL JOURNAL, 2021, 23 (03) : 418 - 425
12345